GC with EphA2 overexpression may show a greater possibility of invisible metastasis (62), distant metastasis (63), tumor invasion, worse clinical staging (51, 56, 60, 64, 65), recurrence (62), tumor differentiation (60), and poor prognosis (64). Here, EPHA2 is linked to gastric cancer.